Virus-Like Particle & Nano-Particle Vaccines

4-6 June 2014, Salk Institute for Biological Studies, La Jolla, California, USA

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Final Conference Programme | Wednesday 4th June

08.00 onwards
Registration

09.30-09.40
Welcome to the Salk Institue & Opening Remarks
Greg Lemke (Salk Institute, La Jolla, California, USA)

SESSION 1:
OPENING PLENARY I

Moderator: Richard W. Compans (Emory University, Atlanta, Georgia, USA)

09.40-10.20
‘The background and development of rotavirus and norovirus VLP vaccines for prevention of gastroenteritis in children’
Timo Vesikari (University of Tampere, Tampere, Finland)

10.20-10.50
‘Primary and secondary B cell responses induced by VLPs’
Martin Bachmann (University of Oxford, Oxford, UK/University of Zurich, Zurich, Switzerland)

10.50-11.20
Coffee Break & Poster Set-Up

SESSION 2:
PLENARY II

Moderator: George P. Lomonossoff (John Innes Centre, Colney, Norwich, UK)

11.20-11.50
‘Designing Ebola VLP vaccines to avoid immune subversion’
Richard W. Compans (Emory University, Atlanta, Georgia, USA)

11.50-12.20
‘RSV fusion (F) nanoparticle immunogenicity in man: A new approach to vaccines?’
Greg Glenn (Novavax Inc., Gaithersburg, Maryland, USA)

12.20-12.50
‘Plant-produced influenza VLP vaccines and beyond’
Marc-Andre D’Aoust (Medicago, Quebec City, Quebec, Canada)

12.50-14.00
Lunch Break & Posters

SESSION 3:
IMMUNE RESPONSES

Moderator: Bryce Chackerian (University of New Mexico, Albuquerque, New Mexico, USA)

14.00-14.25
‘Impact of virus-like particle associated glycoprotein structure on immune responses’
Madelyn R. Schmidt, Lori W. McGinnes, Sarah Kenward, Robert Woodland and Trudy G. Morrison
(University of Massachusetts Medical School, Worcester, Massachusetts, USA)

14.25-14.50
‘Generating optimal VLP-specific antibody responses using mucosal delivery routes and formulations’
Melissa Herbst-Kralovetz (University of Arizona, Phoenix, Arizona, USA)

14.50-15.15
‘Anti-glycan immunity from virus-like particle platforms’
M.G. Finn, Zinaida Polonskaya, Marta Comellas-Aragones, Katarzyna Kaczanowska, Lisa Kain, Shenglou Deng, Paul Savage and Luc Teyton (The Scripps Research Institute and Georgia Institute of Technology, Atlanta, Georgia, USA)

15.15-15.40
‘Virus-like particle immunization of peripheral blood lymphocyte engrafted humanized mice for the analysis of human immune responses’
Madelyn R. Schmidt, Trudy G. Morrison, Sarah A. Kenward, Lori W. McGinnes, George K. Lewis, Dale Greiner and Robert T. Woodland (University of Massachusetts medical School, Worcester, Massachusetts, USA)

15.40-16.00
‘Mannosylation enhances uptake of VLP by murine and human antigen presenting cells’
Vernon Ward, Farah Al-Barwani, Sarah Young, Margaret Baird and David Larsen (University of Otago, Dunedin, New Zealand)

16.00-16.20
‘Immune humoral response in mice elicited by inoculation with native and recombinant Triatoma Virus-VLPs’
Diego M.A. Guerin, Jailson F.B. Querido, Ruben Sanchez-Eugenia, Gerardo A. Marti, Jose F. Rodriguez and Marcelo Sousa Silva (The University of the Basque Country, Bizkaia, Spain)

16.20-16.35
Tea Break & Posters

SESSION 4:
NANOPARTICLE VACCINES

Moderator: Trudy G. Morrison (University of Massachusetts Medical School, Worcester, Massachusetts, USA)

16.35-16.55
‘Mechanisms of inflammatory cell targeting by viral nanoparticles’
Marianne Manchester (University of California at San Diego, San Diego, California, USA)

16.55-17.15
‘Self-assembly of influenza antigens into nanoclusters as candidate universal vaccines’
Baozhong Wang, Li Wang, Annie Hess, Julie A. Champion*, Richard W. Compans (Emory University Schoool of Medicine and *Georgia Institute of Technology, Atlanta, Georgia, USA)

17.15-17.35
‘A broadly multivalent next generation PRINT nanoparticle pneumococcal vaccine induces potent B- and T-cell responses’
Shyam Rele, Anton Beletskii, Camille Bernasconi, Jinny Conley, Meredith Earl, Gabe Fawcett, Jeremy Hansen, Lara Kelly, Marquita Lily, Frank Malinoski, Joseph Marchand, Nicole Meyer, RiLee Robeson, Michele Stone, Ben Yerxa, Jeff Maisonneuve and Mark Alderson (Liquidia Technologies, Morrisville, North Carolina, USA)

17.35-17.55
‘Immune-tolerant elastin-like polypeptide (iTEP) nanoparticles promote peptide vaccine presentation by dendritic cells’

Mingnan Chen, Shuyun Dong and Scott Cho (University of Utah, Salt Lake City, Utah, USA)

 

VLPNPV 2014 Delegates

Login details will be supplied after you have registered for the event.

VLPNPV 2014 Venue


VLPNPV 2014 Sponsors

  • SALK Institute
  • VLP Biotech
  • Matrivax
  • Vedantra Pharmaceuticals
  • Univac
  • Aldevron
  • Vironova
  • Vaccine Research Center
  • Fraunhofer USA
  • Takeda
  • Sanofi Pasteur
  • Medigen
  • NatureGeneTherapy.com
  • Malvern
  • John Innes Centre
  • Novavax
  • Izon
  • Medicago
  • Virometix Vaccines
  • Mucosis

VLPNPV 2014 Downloads

VLPNPV 2014 Leaflet

VLPNPV 2014 Mailing List

Name
E-mail Address
What is 2+6-2?